Your browser doesn't support javascript.
loading
Afatinib plus vinorelbine versus trastuzumab plus vinorelbine in patients with HER2-overexpressing metastatic breast cancer who had progressed on one previous trastuzumab treatment (LUX-Breast 1): an open-label, randomised, phase 3 trial.
Harbeck, Nadia; Huang, Chiun-Sheng; Hurvitz, Sara; Yeh, Dah-Cherng; Shao, Zhimin; Im, Seock-Ah; Jung, Kyung Hae; Shen, Kunwei; Ro, Jungsil; Jassem, Jacek; Zhang, Qingyuan; Im, Young-Hyuck; Wojtukiewicz, Marek; Sun, Qiang; Chen, Shin-Cheh; Goeldner, Rainer-Georg; Uttenreuther-Fischer, Martina; Xu, Binghe; Piccart-Gebhart, Martine.
Afiliación
  • Harbeck N; Brustzentrum der Universität München and Comprehensive Cancer Center of the Ludwig-Maximilians-Universität München, Munich, Germany.
  • Huang CS; National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Taiwan Breast Cancer Consortium, Taipei, Taiwan.
  • Hurvitz S; University of California, Los Angeles, Los Angeles, CA, USA; Translational Research in Oncology, Los Angeles, CA, USA.
  • Yeh DC; Taiwan Breast Cancer Consortium, Taipei, Taiwan; Taichung Veterans General Hospital, Taichung, Taiwan.
  • Shao Z; Fudan University Shanghai Cancer Center, Shanghai, China.
  • Im SA; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
  • Jung KH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Shen K; Comprehensive Breast Health Center, Rui Jin Hospital, Shanghai, China.
  • Ro J; National Cancer Center, Goyang, South Korea.
  • Jassem J; Medical University, Gdansk, Poland.
  • Zhang Q; Cancer Hospital of Harbin Medical University, Harbin, China.
  • Im YH; Samsung Medical Center, Seoul, South Korea.
  • Wojtukiewicz M; Comprehensive Cancer Centre, Medical University, Bialystok, Poland.
  • Sun Q; Peking Union Medical College Hospital, Beijing, China.
  • Chen SC; Taiwan Breast Cancer Consortium, Taipei, Taiwan; Chang Gung Memorial Hospital at Linkou, Chang Gung University College of Medicine, Taoyuan, Taiwan.
  • Goeldner RG; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
  • Uttenreuther-Fischer M; Boehringer Ingelheim Pharma GmbH & Co KG, Biberach an der Riss, Germany.
  • Xu B; Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, China; Peking Union Medical College, Beijing, China. Electronic address: bhxu@hotmail.com.
  • Piccart-Gebhart M; Institut Jules Bordet, Brussels, Belgium.
Lancet Oncol ; 17(3): 357-366, 2016 Mar.
Article en En | MEDLINE | ID: mdl-26822398
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quinazolinas / Vinblastina / Neoplasias de la Mama / Receptor ErbB-2 / Trastuzumab / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Alemania
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Quinazolinas / Vinblastina / Neoplasias de la Mama / Receptor ErbB-2 / Trastuzumab / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2016 Tipo del documento: Article País de afiliación: Alemania